| Nusinersen versus sham control in later-onset spinal muscular atrophy E Mercuri, BT Darras, CA Chiriboga, JW Day, C Campbell, AM Connolly, ... New England Journal of Medicine 378 (7), 625-635, 2018 | 1234 | 2018 |
| The TREAT‐NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations CL Bladen, D Salgado, S Monges, ME Foncuberta, K Kekou, K Kosma, ... Human mutation 36 (4), 395-402, 2015 | 703 | 2015 |
| Ataluren treatment of patients with nonsense mutation dystrophinopathy K Bushby, R Finkel, B Wong, R Barohn, C Campbell, GP Comi, ... Muscle & nerve 50 (4), 477-487, 2014 | 501 | 2014 |
| Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial CM McDonald, C Campbell, RE Torricelli, RS Finkel, KM Flanigan, ... The Lancet 390 (10101), 1489-1498, 2017 | 445 | 2017 |
| Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo‐controlled clinical trial C Campbell, HJ McMillan, JK Mah, M Tarnopolsky, K Selby, T McClure, ... Muscle & nerve 55 (4), 458-464, 2017 | 229 | 2017 |
| Consensus-based care recommendations for adults with myotonic dystrophy type 1 T Ashizawa, C Gagnon, WJ Groh, L Gutmann, NE Johnson, G Meola, ... Neurology: Clinical Practice 8 (6), 507-520, 2018 | 163 | 2018 |
| Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database Z Koeks, CL Bladen, D Salgado, E Van Zwet, O Pogoryelova, ... Journal of neuromuscular diseases 4 (4), 293-306, 2017 | 157 | 2017 |
| Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled … E Mercuri, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, ... The Lancet Neurology 21 (1), 42-52, 2022 | 134 | 2022 |
| Treating pediatric neuromuscular disorders: the future is now JJ Dowling, H D. Gonorazky, RD Cohn, C Campbell American Journal of Medical Genetics Part A 176 (4), 804-841, 2018 | 134 | 2018 |
| A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy N Goemans, E Mercuri, E Belousova, H Komaki, A Dubrovsky, ... Neuromuscular Disorders 28 (1), 4-15, 2018 | 123 | 2018 |
| The TREAT‐NMD D uchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia CL Bladen, K Rafferty, V Straub, S Monges, A Moresco, H Dawkins, A Roy, ... Human mutation 34 (11), 1449-1457, 2013 | 109 | 2013 |
| Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe CL Bladen, R Thompson, JM Jackson, C Garland, C Wegel, A Ambrosini, ... Journal of neurology 261, 152-163, 2014 | 108 | 2014 |
| Congenital myotonic dystrophy: assisted ventilation duration and outcome C Campbell, R Sherlock, P Jacob, M Blayney Pediatrics 113 (4), 811-816, 2004 | 93 | 2004 |
| De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy M Zarrei, DL Fehlings, K Mawjee, L Switzer, B Thiruvahindrapuram, ... Genetics in Medicine 20 (2), 172-180, 2018 | 90 | 2018 |
| Medical and cognitive outcome in children with traumatic brain injury CGN Campbell, SM Kuehn, PMP Richards, E Ventureyra, JS Hutchison Canadian journal of neurological sciences 31 (2), 213-219, 2004 | 90 | 2004 |
| Deflazacort for the treatment of Duchenne Dystrophy: a systematic review C Campbell, P Jacob BMC neurology 3, 1-10, 2003 | 83 | 2003 |
| Efficient computation of forward kinematics and Jacobian matrix of a Stewart platform-based manipulator CC Nguyen, ZL Zhou, SS Antrazi, CE Campbell IEEE Proceedings of the SOUTHEASTCON'91, 869-874, 1991 | 79 | 1991 |
| A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy RG Victor, HL Sweeney, R Finkel, CM McDonald, B Byrne, M Eagle, ... Neurology 89 (17), 1811-1820, 2017 | 76 | 2017 |
| Congenital myotonic dystrophy: Canadian population-based surveillance study C Campbell, S Levin, VM Siu, S Venance, P Jacob The Journal of Pediatrics 163 (1), 120-125. e3, 2013 | 76 | 2013 |
| Infantile muscular dystrophy in Canadian aboriginals is an αB‐crystallinopathy MR Del Bigio, AE Chudley, HB Sarnat, C Campbell, S Goobie, ... Annals of neurology 69 (5), 866-871, 2011 | 76 | 2011 |
